Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Griffiths, C.E.M.; Bruin‐Weller, Marjolein de; Deleuran, Mette; Fargnoli, Maria Concetta; Staumont‐Sallé, D.; Hong, Chih‐Ho; Sánchez‐Carazo, J.L.; Foley, Peter; Seo, Seong Jun; Msihid, Jérôme; Chen, Zhe; Cyr, Sonya; Rossi, Ana B.

doi:10.1007/s13555-021-00558-0

Cited by 24 publications

(30 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A trend of high response to dupilumab at month 4 or month 12 was observed in patients with prior asthma, although the proportion of response to dupilumab at month 4 ( p = 0.074) was not significantly different from baseline in these patients. A previous study demonstrated that AD patients with prior systemic non-steroidal immunosuppressants (NSISS) (e.g., cyclosporine, methotrexate, azathioprine, or mycophenolate mofetil) use had a lower EASI reduction at week 16 than that in patients without prior NSISS use [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study

Yang

Lai

Chen

et al. 2022

JCM

View full text Add to dashboard Cite

To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18–87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator’s Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month 12, while prurigo and lichenoid phenotypes were associated with a lower proportion of EASI-75 at month 12. However, the majority of adverse events were mild in severity. In conclusion, our study results identify phenotype-related dupilumab response at month 12 in adults with moderate-to-severe AD, and we suggest that treatment should not be discontinued until reaching a satisfactory clinical response.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study

Yang

Lai

Chen

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Matched healthy controls were recruited via advertisements. To reduce heterogeneity, the study inclusion criteria for subjects with AD were: 1) presence of atopy established by positive aeroallergen skin prick test and/or elevated serum total IgE levels; and 2) moderate-to-severe AD defined as an EASI score ≥ 17 and investigator global assessment score ≥ 3 [ 43 ]. These AD severity tools have previously been validated for AD severity scoring [ 43 , 44 ].…”

Section: Methodsmentioning

confidence: 99%

“…To reduce heterogeneity, the study inclusion criteria for subjects with AD were: 1) presence of atopy established by positive aeroallergen skin prick test and/or elevated serum total IgE levels; and 2) moderate-to-severe AD defined as an EASI score ≥ 17 and investigator global assessment score ≥ 3 [ 43 ]. These AD severity tools have previously been validated for AD severity scoring [ 43 , 44 ]. Control subjects were included if they had no history of atopic disease and displayed negative results from aeroallergen skin prick testing performed at their enrollment visit.…”

Section: Methodsmentioning

confidence: 99%

Epigenetic and transcriptional dysregulation in CD4+ T cells in patients with atopic dermatitis

et al. 2022

View full text Add to dashboard Cite

Atopic dermatitis (AD) is one of the most common skin disorders among children. Disease etiology involves genetic and environmental factors, with 29 independent AD risk loci enriched for risk allele-dependent gene expression in the skin and CD4+ T cell compartments. We investigated the potential epigenetic mechanisms responsible for the genetic susceptibility of CD4+ T cells. To understand the differences in gene regulatory activity in peripheral blood T cells in AD, we measured chromatin accessibility (an assay based on transposase-accessible chromatin sequencing, ATAC-seq), nuclear factor kappa B subunit 1 (NFKB1) binding (chromatin immunoprecipitation with sequencing, ChIP-seq), and gene expression levels (RNA-seq) in stimulated CD4+ T cells from subjects with active moderate-to-severe AD, as well as in age-matched and non-allergic controls. Open chromatin regions in stimulated CD4+ T cells were highly enriched for AD genetic risk variants, with almost half of the AD risk loci overlapping AD-dependent ATAC-seq peaks. AD-specific open chromatin regions were strongly enriched for NF-κB DNA-binding motifs. ChIP-seq identified hundreds of NFKB1-occupied genomic loci that were AD- or control-specific. As expected, the AD-specific ChIP-seq peaks were strongly enriched for NF-κB DNA-binding motifs. Surprisingly, control-specific NFKB1 ChIP-seq peaks were not enriched for NFKB1 motifs, but instead contained motifs for other classes of human transcription factors, suggesting a mechanism involving altered indirect NFKB1 binding. Using DNA sequencing data, we identified 63 instances of altered genotype-dependent chromatin accessibility at 36 AD risk variant loci (30% of AD risk loci) that might lead to genotype-dependent gene expression. Based on these findings, we propose that CD4+ T cells respond to stimulation in an AD-specific manner, resulting in disease- and genotype-dependent chromatin accessibility alterations involving NFKB1 binding.

show abstract

“…AD affects the face, extensor surfaces of the body, fold of arms, legs, Sole, Palm and neck. The prevalence of AD is 20% (5%-30% in the paediatric and 1%-10% in the adult population) worldwide; 12%-14% in Africa; 6%-10% in Latin America; 3%-6% in Asian-Pacific countries, Eastern Mediterranean region, and India [5,6,7] . Over the last 40 years, the incidence of AD has risen, it appears to be commoner in urban & semi-urban areas than in rural areas and in the industrialised as opposed to less industrialised countries [6,7,8] .…”

Section: Introductionmentioning

confidence: 99%

Homoeopathic management can cure non-communicable chronic Atopic Eczema (Dermatitis) with Sleeplessness, indigestion and depression: A case report upon neurodermatitis

Das¹,

Sarkar²,

Sabud³

2022

Int. J. Homoeopathic Sci.

View full text Add to dashboard Cite

Atopic dermatitis (AD) also known as atopic eczema is a chronic inflammatory dermatosis characterised by pruritus & chronicity due to antigen-antibody reaction manifesting on skin conditions associated with intra & intercellular Creaked & oedema. The prevalence of AD is 20% (5%-30% in the paediatric and 1%-10% in the adult population) worldwide; 3%-6% in Asian-Pacific countries, Eastern Mediterranean region, and India. A Hindu 45 years female chief complains were hot, dry skin in all over the body, dry eruption with a small brown-black scab in both palms, lower abdomen & soles. Ulcer formation corrodes & becomes deeper like punched-out edges with a tendency to penetrate and tenacious exudation without spreading in circumference & she suffered for 3-4 years. We evaluated this case on SCORAD Index & Assessment by Modified Naranjo Criteria Score. This case report highlighted the mental symptoms followed by physical & particular symptoms. The study was clearly shown the good scope of homoeopathic remedies work for treatment of Atopic Eczema (Dermatitis) along with mental complaints like, depression, anxiety, ill humour, low spirit, sleeplessness etc. There have some limitations to Atopic Eczema (Dermatitis) like, Sever bronchial asthma, hay fever, Alzheimer's disease, Multiple Sclerosis etc.

show abstract

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Cited by 24 publications

References 40 publications

Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study

Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study

Epigenetic and transcriptional dysregulation in CD4+ T cells in patients with atopic dermatitis

Homoeopathic management can cure non-communicable chronic Atopic Eczema (Dermatitis) with Sleeplessness, indigestion and depression: A case report upon neurodermatitis

Contact Info

Product

Resources

About